A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
Summary
The purpose of this study is to look at whether the investigational product, rocatinlimab, works, and how safe it is for moderate to severe asthma.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 75
Inclusion criteria:
You might be eligible if:
1) 18 to 75 years of age
2) you have moderate to severe asthma.
Exclusion criteria:
You might not be eligible if:
1) you do not have moderate to severe asthma
2) you are under the age of 18
3) you are pregnant or breastfeeding.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you would like to learn more about how you can get involved with this study, please contact our study coordinator, Madison, at 403-220-7827.
Principal investigator:
Richard Leigh
Clinical trial:
Yes
REB-ID:
REB24-0432